- Home
- VZIO vs KNSA Comparison
VZIO vs KNSA Comparison
Compare VZIO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VZIO
- KNSA
- Stock Information
- Founded
- VZIO 2002
- KNSA 2015
- Country
- VZIO United States
- KNSA United Kingdom
- Employees
- VZIO N/A
- KNSA N/A
- Industry
- VZIO Consumer Electronics/Appliances
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VZIO Consumer Staples
- KNSA Health Care
- Exchange
- VZIO Nasdaq
- KNSA Nasdaq
- Market Cap
- VZIO 2.3B
- KNSA 2.0B
- IPO Year
- VZIO 2021
- KNSA 2018
- Fundamental
- Price
- VZIO $11.25
- KNSA $24.93
- Analyst Decision
- VZIO Hold
- KNSA Buy
- Analyst Count
- VZIO 9
- KNSA 4
- Target Price
- VZIO $10.75
- KNSA $32.00
- AVG Volume (30 Days)
- VZIO 1.6M
- KNSA 281.0K
- Earning Date
- VZIO 08-07-2024
- KNSA 10-29-2024
- Dividend Yield
- VZIO N/A
- KNSA N/A
- EPS Growth
- VZIO 57.67
- KNSA N/A
- EPS
- VZIO 0.08
- KNSA N/A
- Revenue
- VZIO $1,719,900,000.00
- KNSA $338,930,000.00
- Revenue This Year
- VZIO $8.45
- KNSA $59.11
- Revenue Next Year
- VZIO $9.82
- KNSA $36.07
- P/E Ratio
- VZIO $148.41
- KNSA N/A
- Revenue Growth
- VZIO 0.01
- KNSA 20.69
- 52 Week Low
- VZIO $4.82
- KNSA $14.12
- 52 Week High
- VZIO $11.30
- KNSA $27.92
- Technical
- Relative Strength Index (RSI)
- VZIO 63.08
- KNSA 45.04
- Support Level
- VZIO $11.20
- KNSA $26.26
- Resistance Level
- VZIO $11.30
- KNSA $27.25
- Average True Range (ATR)
- VZIO 0.08
- KNSA 0.88
- MACD
- VZIO 0.00
- KNSA -0.34
- Stochastic Oscillator
- VZIO 73.81
- KNSA 12.06
About VZIO VIZIO Holding Corp.
VIZIO Holding Corp operates two distinct integrated businesses: Device and Platform+. Through Device business, it offers a range of high-performance Smart TVs designed to address specific consumer preferences, as well as a portfolio of soundbars that deliver immersive audio experiences. It generates revenue from the shipment of these devices to retailers and distributors across the United States, as well as directly to consumers through the website. The Company's reportable segments: Device, and Platform+T. It derives maximum revenue from Device Segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.